Shots:

• Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies
• In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie with $26.13B reported segment revenue ranks first in our list followed by Johnson & Johnson and Sanofi
• PharmaShots brings a concise report on the Top 20 Immunology Companies Based on 2023 Immunology Segment Total Revenue

Note: Columns 1 and 2 represent ranks and companies, while Columns 3, 4, and 5 showcase the total immunology revenue of 2022, the total revenue of 2023, and the percentage change.

20. Organon & Co. 

Immunology Segment Revenue: $0.65B

Founded Year: 2020

Market Cap: $5.56B

Total Employees: 10,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

• A global healthcare company, Organon research, discovers, develops, and commercializes medicinal products for women's health
• In immunology, the company develops Arcoxia (etoricoxib) and three biosimilars Hadlima (adalimumab-bwwd), Brenzys (etanercept), & Renflexis (infliximab-abda). In 2023, the immunology revenue increased by 16.22% as compared to the 2022, mainly due to the increased sales of Renflexis and Arcoxia
• In Aug’23, Samsung Bioepis and Organon reported overall results of the interchangeability study of SB5 Humira biosimilar

19. Merck & Co. 

Immunology Segment Revenue: $0.89B

Founded Year: 1891

Market Cap: $318.93B

Total Employees: 69,000

Headquarters: Rahway, New Jersey

Stock Exchange: NYSE

• Merck offers innovative therapeutic solutions by developing and producing medicines, vaccines, biological treatments, and health products for animals and humans. The corporation splits its operations into two segments: pharmaceutical and animal health
• Simponi and Remicade are the two products for autoimmune diseases under the pharmaceutical segment. In 2023, the immunology revenue of Merck decreased by 1.75% due to decreased sales of Remicade
• In 2023, Aqilion announced an exclusive license and strategic research collaboration with Merck to discover, develop, and commercialize small molecule inhibitors

18. Argenx

Immunology Segment Revenue: $1.19B

Founded Year: 2008

Market Cap: $29.81B

Total Employees: ~1400

Headquarters: Amsterdam, Netherlands

Stock Exchange: EBR

• Argenx is a commercial-stage biopharmaceutical company that focuses on developing and commercializing antibody-based therapies for the treatment of autoimmune diseases
• Argenx's immunology segment comprises VYVGART and VYVGART Hytrulo. In 2023, immunology sales increased by 197.16% as compared to 2022 owing to increased sales of VYVGART in the United States and as well in ROW
• In Nov’2023, Argenx announced the EC approval of Subcutaneous VYVGART (efgartigimod alfa and hyaluronidase-qvfc) for generalized myasthenia gravis

17. Astellas

Immunology Segment Revenue: $1.43B

Founded Year: 1923

Market Cap: $19.72B

Total Employees: ~14,500

Headquarters: Tokyo, Japan

Stock Exchange: TYO

• Astellas is a multinational pharmaceutical company that focuses on genetic regulation, immuno-oncology, blindness & regeneration, and targeted protein degradation  
• Astellas’ only immunology product Prograf (tacrolimus) comes in different formulations, including Advagraf, Graceptor, and ASTAGRAF XL. In 2023, segment revenue dipped by 3.90% as compared to 2022 sales, owing to the lower sales of Prograf[AS2]  mainly in Japan and the US
• In Apr’2023, Twist Bioscience extended its collaboration with Astellas by entering into a third collaboration to support antibody discovery for Immunotherapies  

16. Mitsubishi Tanabe Pharma (Mitsubishi Chemical Group)

Immunology Segment Revenue: $1.70B

Founded Year: 1993

Market Cap: $8.45B

Total Employees: ~68,600

Headquarters: Osaka, Japan

Stock Exchange: TYO

• Mitsubishi Tanabe Pharma Corporation (MTPC) is the pharmaceutical division of Mitsubishi Chemical Group (MCG) that manufactures and commercializes ethical drugs   
• The total immunology revenue generated by autoimmune products Stelara, Simponi & Gilenya (Royalty revenue) increased the sales by 101.77% in 2023 as compared to 2022, owing to the royalty revenue of Gilenya
• In Nov’23, Mitsubishi Tanabe Pharma Corporation entered into a license agreement with Kynexis for neuropsychiatric drug candidate MT-5356

15. GSK

Immunology Segment Revenue: $1.71B

Founded Year: 2000

Market Cap: $80.78B

Total Employees: ~70,200

Headquarters: London, United Kingdom

Stock Exchange: LON

• GSK is a British multinational biopharma company that researches, discovers, manufactures, and commercializes therapies for infectious diseases, HIV, immunology, respiratory, and cancer
• GSK's only immunology asset is Benlysta, which contributed to the total immunology sales of the company and showed an increment of 23.85% in 2023 as compared to 2022, due to strong demand for Benlysta in the US and Europe
• In Feb’23, GSK’s Benlysta received an Orphan Drug Designation from the US FDA for the possible treatment of systemic sclerosis

14. UCB

Immunology Segment Revenue: $2.46B

Founded Year: 1928

Market Cap: $31.12B

Total Employees: ~9,100

Headquarters: Brussels, Belgium

Stock Exchange: EBR

• A multinational biopharma company, UCB develops, manufactures, and commercializes therapies in neurology, immunology, and rare diseases 
• In immunology, UCB has two products Cimzia & Bimzelx. UCB reported an increase of 8.43% in the segment revenue in 2023 as compared to 2022, owing to increased sales of Bimzelx
• In Oct’23, Bimzelx received the US FDA's approval for the medical care of adults with mild to severe plaque psoriasis

13. Pfizer

Immunology Segment Revenue: $3.02B

Founded Year: 1849

Market Cap: $169.88B

Total Employees: 88,000

Headquarters: New York, United States

Stock Exchange: NYSE

• Pfizer is an American multinational company that develops, manufactures, and markets medicines and vaccines. The company operates in three main segments: Primary care, specialties, and oncology
• Xeljanz, Enbrel, and Inflectra/Remsima are the products that fall in the immunology segment. In 2023 Pfizer’s immunology revenue decreased by 9.24% as compared to 2022, owing to the reduced sales of Xeljanz and Enbrel
• In Oct’2023, the US FDA approved Pfizer’s VELSIPITY for the treatment of moderately to severely active ulcerative colitis in adult patients

12. Incyte

Immunology Segment Revenue: $3.09B

Founded Year: 2002

Market Cap: $15.02B

Total Employees: ~2300

Headquarters: Delaware, United States

Stock Exchange: NASDAQ

• A global biopharmaceutical company, Incyte discovers, develops, and commercializes proprietary therapeutics. The company works in areas of Hematology/Oncology and Inflammation & Autoimmunity
• Incyte’s Jakafi, Olumiant, and Jakavi (royalty revenue) are the products approved for autoimmune indications. In 2023, the company reported an increase of 7.72% in its segment revenue as compared to 2022, owing to the increased sales of Jakafi
• In 2023, Incyte reported encouraging 52-week outcomes from a P-IIb trial assessing Povorcitinib (INCB54707) in individuals having extensive nonsegmental vitiligo

11. Eli Lilly & Company

Immunology Segment Revenue: $3.79B

Founded Year: 1876

Market Cap: $817.23B

Total Employees: 43,000

Headquarters: Indianapolis, United States

Stock Exchange: NYSE

• Eli Lilly is an American pharmaceutical company that specializes in bone and joint disease, cancer, cardiovascular disease, diabetes, endocrine illness, immunology, neurodegeneration, neurology, and pain management
• The immunology segment of Eli Lilly includes drugs like Taltz and Olumiant among others. In 2023, the immunology segment showed an incline of 13.54% in revenue as compared to 2022, due to increased sales of the above-mentioned drugs  
• In 2023, Eli Lilly completed the acquisition of DICE therapeutics and expanded its immunology portfolio by including oral IL-17 inhibitors

10. Bristol-Myers Squibb

Immunology Segment Revenue: $4.20B

Founded Year: 1887

Market Cap: $90.53B

Total Employees: 34,100

Headquarters: New Jersey, United States

Stock Exchange: NYSE

• BMS is an American biopharma company that discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products on a global basis
• The company has three autoimmune products Orencia, Sotyktu, and Zeposia. Orencia contributed the most to the total immunology revenue. The company's immunology revenue in 2023 increased by 12.97% as compared to 2022, owing to the overall increased sales of autoimmune products  
• In 2023, BMS and Zenas BioPharma entered into a strategic license and collaboration agreement to develop and commercialize novel bi-functional antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

09. Biogen

Immunology Segment Revenue: $5.40M

Founded Year: 1978

Market Cap: $32.91B

Total Employees: ~8700

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

• Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative treatments for Alzheimer’s, lupus, multiple sclerosis, and other therapy areas
• Tysabri, Flixabi, Tecfidera, Vumerity, Avonex, Plegridy, Fampyra, Benepali, and Imraldi are the approved products of Biogen for autoimmune indications. In 2023, the immunology segment faced a decline of 12.57% as compared to 2022, due to low reported sales of Tecfidera
• In 2023, the FDA approved Biogen's Tofidence (tocilizumab-bavi), a biosimilar to Actemra

08. Takeda

Immunology Segment Revenue: $5.58B

Founded Year: 1781

Market Cap: $44.19B

Total Employees: ~49,300

Headquarters: Tokyo, Japan

Stock Exchange: TYO

• Takeda is a multinational pharmaceutical company that focuses on five key business areas, including Gastrointestinal, Rare diseases, PDT Immunology, Oncology, and Neuroscience  
• The company's PDT Immunology segment includes immunoglobulin products and Albumin products. In 2023, the segment revenue increased by 13.18% as compared to 2022, owing to the increased sales of the PDT Immunology products
• In 2023, Takeda received US FDA approval to expand the use of Hyqvia to treat primary immunodeficiency in children

07. AstraZeneca

Immunology Segment Revenue: $6.39B

Founded Year: 1999

Market Cap: $236.64B

Total Employees: 89,900

Headquarters: Cambridge, United Kingdom

Stock Exchange: LON

• AstraZeneca discovers, develops, and commercializes medicines in oncology, cardiovascular, renal, metabolic, respiratory, and immunology, vaccines and immune therapies, and rare diseases  
• Saphnelo, Soliris, and Ultomiris are AstraZeneca's immunology products. In 2023, Soliris' revenue contributed the most to the immunology segment by adding $3,145M to the revenue. In 2023, the company's immunology revenue increased by 9.36% as compared to 2022, majorly driven by the increased sales of Ultomiris
• In 2023, AstraZeneca announced its intentions to acquire Gracell Biotechnologies, which was finalized in 2024. This acquisition broadened the company's focus on cancer and autoimmune diseases

06. Roche

Immunology Segment Revenue: $7.64B

Founded Year: 1896

Market Cap: $260.23B

Total Employees: 100,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

• Roche is a global multinational healthcare company that discovers, develops, and commercializes therapeutic and diagnostic products. The company operates under two business segments, i.e. Pharmaceuticals and Diagnostics   
• Actemra/RoActemra, Xolair, and MabThera/Rituxan are the products under the immunology segment of Roche. In 2023, immunology showed a slight growth in its revenue by generating 1.25% more revenue than in 2022, due to higher sales of Actemra/RoActemra and Xolair
• In 2023, Roche completed the acquisition of Telavant from Roivant, including rights to a novel TL1A-directed antibody (RVT-3101) for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease

05. Novartis

Immunology Segment Revenue: $13B

Founded Year: 1996

Market Cap: $239.30B

Total Employees: ~19,600

Headquarters: Basel, Switzerland

Stock Exchange: SWX

• An innovative medicines company, Novartis discovers, develops, and sells products in cardiovascular, renal, metabolic (CRM), immunology, neuroscience, and oncology 
• Cosentyx, Xolair, Ilaris, Gilenya, Kesimpta, Mayzent, and Jakavi are the company's immunology products. In 2023, the total immunology revenue increased by 5.65% as compared to 2022, owing to the higher sales of immunology medicines 
• In 2023, the US FDA approved Novartis’ Cosentyx as the first new biologic for the treatment of hidradenitis suppurativa patients  

04. Amgen

Immunology Segment Revenue: $13.31B

Founded Year: 1980

Market Cap: $180.03B

Total Employees: 26,700

Headquarters: California, United States

Stock Exchange: NASDAQ

• Amgen is a global biotech company that discovers, develops, manufactures, and delivers innovative therapies. The company focuses on cardiovascular diseases, oncology, bone health, neuroscience, nephrology, and inflammation
• Enbrel, Otezla, Tavneos, Tepezza, Uplizna, Prolia, Xgeva, and Amjevita are the company’s key autoimmune products. In 2023, the immunology revenue inclined 32.2% as compared to 2022, predominantly due to the overall increased sales of all the autoimmune products
• In 2023, Amgen launched Amjevita the first biosimilar of Humira in the United States   

03. Sanofi

Immunology Segment Revenue: $14.22B

Founded Year: 1956

Market Cap: $130.14B

Total Employees: ~86,100

Headquarters: Paris, France

Stock Exchange: NASDAQ

• Sanofi is a global French pharmaceutical and healthcare company that researches, develops, manufactures, and markets pharmaceutical products in immunology and inflammation, neurology, oncology, rare blood disorders, rare diseases, and vaccines   
• Dupixent, Kevzara, Enjaymo, Aubagio, Thymoglobulin, and Rezurock are Sanofi's immunology products. In 2023, the segment revenue grew by 40 percent as compared to 2022 owing to increased sales of Dupixent
• In 2023, Sanofi’s anti-CD40L antibody frexalimab demonstrated positive P-II results in relapsing multiple sclerosis by reducing disease activity  

02. Johnson & Johnson

Immunology Segment Revenue: $18.05B

Founded Year: 1886

Market Cap: $376.12B

Total Employees: 131,900

Headquarters: New Jersey, United States

Stock Exchange: NYSE

• Johnson & Johnson is a global healthcare company that provides new medications and MedTech solutions in oncology, immunology, neuroscience, cardiology, pulmonary hypertension, and ophthalmology
• Remicade, Simponi/Simponi Aria, Stelara, and Tremfya among others are the company's immunology products. In 2023, the immunology segment revenue increased by 6.59% as compared to 2022, owing to the higher sales of Stelara and Tremfya
• In 2023, Janssen announced encouraging topline results for JNJ-2113, an oral IL-23 receptor antagonist peptide under development for the treatment of moderate-to-severe plaque psoriasis

01. AbbVie

Immunology Segment Revenue: $26.13B

Founded Year: 2013

Market Cap: $311.16B

Total Employees: 50,000

Headquarters: Illinois, United States

Stock Exchange: NYSE

• AbbVie discovers, manufactures, and commercializes products in oncology, immunology, neuroscience, eye care, aesthetics, and other chronic and complex diseases
• Humira, Skyrizi, and Rinvoq are the three products in Abbvie’s immunology segment. In 2023, Abbvie faced a decline in its total immunology revenue by 9.63% as compared to 2022, owing to the lower sales of Humira
• In 2023, AbbVie and Anima Biotech announced a collaboration to discover and develop mRNA biology modulators against oncology and immunology targets

Sources:

• Annual reports
• SEC Filings
• Press releases
• Company websites

Market Cap Source: Google Finance (25 Jul 2024)

Currency Conversion: X-Rates

Note: Percentage Change in Segment Revenue is calculated on precise value in Millions

Related Post: https://www.pharmashots.com/15863/top-20-immunology-companies-based-on-2022-immunology-segment-total-revenue